Last reviewed · How we verify

NCT02784717: XASSURE

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

Completed Last updated 3 September 2020
What this trial tests

trial testing Rivaroxaban (Xarelto, BAY 59-7939) in Stroke in 3,055 participants. Completed in 24 September 2019.

Timeline
11 May 2016
Primary endpoint
21 February 2019
24 September 2019

Quick facts

Lead sponsorBayer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,055
Start date11 May 2016
Primary completion21 February 2019
Estimated completion24 September 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This non-interventional field study will investigate rivaroxaban under clinical practice conditions for stroke prevention and for prevention of non-CNS systemic embolism in patients with non-valvular atrial fibrillation in China.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).
    Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, et al · · 2019 · cited 8× · PMID 31169831 · DOI 10.1186/s12959-019-0195-7

Verify or expand the search:

Other trials of Rivaroxaban (Xarelto, BAY 59-7939)

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Bayer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02784717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing